Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Boa...
September 28 2016 - 07:30AM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical
company developing small molecule therapeutics to treat diseases
caused by dysfunctional protein processing such as cystic fibrosis
(CF), today announced the appointment of Naimish Patel, M.D., C.M.,
and Elizabeth Tullis, M.D., FRCPC, to its clinical advisory board.
Dr. Patel is currently a Project Leader in Respiratory,
Inflammation and Autoimmunity iMED and Senior Medical Director for
AstraZeneca Pharmaceuticals in Sweden. Dr. Tullis serves as
Director of the Toronto Adult Cystic Fibrosis Clinic at St.
Michael’s Hospital. The recent appointees will join a team of the
world’s leading cystic fibrosis experts, including Richard B. Moss,
M.D.; Jane C. Davies, M.D., FRCPCH; Michael R. Knowles, M.D.; Felix
A. Ratjen, M.D., Ph.D.; Isabelle Sermet-Gaudelus, M.D., Ph.D.; and
Pamela L. Zeitlin, M.D., Ph.D.
"We are thrilled to welcome Drs. Patel and Tullis to our
clinical advisory board. Proteostasis Therapeutics has worked hard
to gather a truly luminary group of advisors, and Drs. Patel and
Tullis will make a significant impact as the company advances
existing clinical and pre-clinical programs in cystic fibrosis,”
said Dr. Richard B. Moss, chairman of the clinical advisory board
for Proteostasis Therapeutics. “Dr. Patel’s knowledge and
experience in translational medicine and early clinical development
focused on cystic fibrosis, coupled with Dr. Tullis’ extensive
research in adult cystic fibrosis, will be invaluable as the
company continues to develop PTI-428 and additional compounds to
expand the therapeutic benefits achievable by CF patients with a
broader set of disease genotypes.”
Dr. Patel joined AstraZeneca in September 2013 and has led early
clinical development teams, as well as pre-clinical development
teams identifying and developing compounds from target
identification to Phase 1 to Phase 2b. Prior to joining
AstraZeneca, Dr. Patel served as Associate Medical Director in the
Clinical Medical Director Group in CF for Vertex Pharmaceuticals,
where he led an early-phase Cystic Fibrosis Transmembrane
conductance Regulator corrector program, the biomarkers task force
and a Phase 3 study program. Dr. Patel is an Attending Physician in
the Intensive Care Unit and Pulmonary Outpatient Services at Beth
Israel Deaconess Medical Center. Dr. Patel earned his undergraduate
degree in mechanical engineering from Massachusetts Institute of
Technology and received a Doctor of Medicine and Master of Surgery
(M.D., C.M.) from McGill University Faculty of Medicine. Dr. Patel
also completed a fellowship in pulmonary and critical care medicine
at Harvard Medical School.
Alongside her role as Director of the Toronto Adult CF Clinic at
St. Michael’s Hospital, Dr. Tullis serves as Professor of Medicine
at the University of Toronto, the Respirology Division Head at St.
Michael’s Hospital, and as an Adjunct Scientist at the Keenan
Research Centre of Li Ka Shing Knowledge Institute. She is the CF
Canada Chair in Adult CF Research and previously served as Chair of
the clinic subcommittee of the Medical/Scientific Advisory Board of
CF Canada. Dr. Tullis has published over 100 articles and book
chapters and has lectured nationally and internationally on issues
related to CF in adults. Dr. Tullis graduated from University of
Toronto Medical School, where she completed internal medicine and
respirology training. She also completed a clinical fellowship in
adult CF in Melbourne, Australia in 1990.
“Proteostasis Therapeutics is making great strides in its
commitment to advancing and improving the treatment of cystic
fibrosis for more than 70,000 patients worldwide living with the
disease,” said Dr. Patel. “I am honored to work alongside the top
experts in this field and to help guide the company’s research
efforts and clinical trial programs into the future.”
“As Proteostasis Therapeutics continues to expand its clinical
programs, I look forward to bringing my experience and expertise to
the table as we work together on such a groundbreaking approach to
treating those with cystic fibrosis,” said Dr. Tullis.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a biopharmaceutical company
dedicated to the discovery of groundbreaking therapies to treat
diseases caused by dysfunctional protein processing, such as cystic
fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis
Therapeutics team focuses on identifying therapies that modulate
the proteostasis imbalance in cells and restore protein function.
Proteostasis Therapeutics is currently enrolling eligible adults
with CF to participate in its Phase 1 clinical trials of PTI-428.
In addition to its multiple programs in cystic fibrosis,
Proteostasis Therapeutics has formed collaborations with Biogen to
research and identify therapeutic candidates for neurodegenerative
disease and with Astellas Pharma, Inc. to research and identify
therapies targeting the Unfolded Protein Response (UPR) pathway.
For more information, visit www.proteostasis.com.
Media Contact:
Katie Engleman, Pure Communications, Inc.
(910) 509-3977
katie@purecommunicationsinc.com
Investor Contact:
Luke Heagle, Pure Communications, Inc.
(910) 726-1372
luke@purecommunicationsinc.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2023 to Mar 2024